Why is hunger coming back on Mounjaro — and what does it actually mean?

The biggest misconception: hunger returning means Mounjaro has stopped working

This is the question our prescribers hear most weeks. Someone notices appetite creeping back a few days before their injection is due, or after a stressful period, and concludes the medicine is failing them. It rarely is. Tirzepatide works by activating two gut-hormone receptors (GIP and GLP-1) to slow how quickly the stomach empties and to signal fullness to the brain, as described in the NHS patient information on tirzepatide. That dual action is real and well-documented. But no medicine creates a flat, unchanging absence of appetite across every hour of every week. Blood levels of tirzepatide rise in the days after each injection and then gradually fall toward the end of the cycle. For many people, the trough (typically in the 24–48 hours before the next injection) is when hunger feels most familiar again.

Recognising that pattern matters. If returning hunger is predictable and tied to the end of your weekly cycle, that is a pharmacological feature, not a failure. If it feels more widespread or sudden, there are usually other factors at play. Sleep deprivation, high stress, a change in eating routine or a recent viral illness can all temporarily blunt the medicine's effect on appetite. None of those situations means the treatment has stopped working.

Worth knowing: this pattern is documented across the clinical literature. The SURMOUNT-1 trial, published in the New England Journal of Medicine, showed average weight reduction of around 20–21% at the 15 mg dose over 72 weeks, but that headline figure is the result of sustained appetite modulation across a long period, not a constant and unwavering suppression at every single point.

When hunger returns after a dose increase, what is actually happening

The tirzepatide schedule starts at 2.5 mg, a dose chosen to let your digestive system adjust rather than to deliver maximum appetite suppression from day one. Moving to 5 mg, 7.5 mg or higher typically brings a renewed reduction in hunger, but in the weeks before a planned increase, some people feel the current dose is no longer as effective as it was initially. That is a real phenomenon, and it is one reason the titration schedule exists, alongside a broader set of changes that unfold as the treatment takes hold, which you can read about in our guide to what to expect as Mounjaro begins to work.

There is an important distinction here, though. Feeling hungrier than you did in week two of a given dose is not the same as the medicine failing. Your body adapts to new signals, including hormonal ones. The prescriber's job is to assess whether returning hunger reflects a sensible point to consider moving to the next dose, or whether addressing a lifestyle factor first makes more sense. A dose increase should be based on a full clinical review, not self-initiated. If you are wondering where you sit in the treatment schedule, the overview of how Mounjaro is used in UK practice covers the licensed dose pathway in more detail.

For people who notice hunger returning specifically around their menstrual cycle, there is a distinct hormonal mechanism worth understanding. Progesterone in the luteal phase is known to increase appetite, and some people on GLP-1 and dual-agonist medicines find that natural hormonal fluctuation is strong enough to partially override appetite suppression for several days each month. This is not a reason to change doses without clinical input, it is a pattern to document and discuss. We have covered that specific picture in more detail for anyone affected by Mounjaro and cycle-related hunger.

Hunger coming back after stopping or pausing Mounjaro

A different kind of hunger return happens when Mounjaro is paused or stopped entirely. This one surprises people because it can feel sudden and intense. Tirzepatide does not rewire appetite permanently. Once the medicine clears the system, the hormonal signals that were being modulated return to their baseline. For some people, appetite returns to where it was before they started treatment; for others it feels heightened initially, possibly because weight loss itself changes circulating levels of appetite hormones such as ghrelin.

This is not a reason to stay on treatment indefinitely if it is not right for you, but it is a reason to have a plan. Any decision to stop should be made with your prescriber, with a clear understanding of what support will be in place afterwards. The reality of coming off the medicine is worth reading about honestly before making that call; the picture is nuanced and the evidence matters. If you are weighing up that decision, the page on stopping Mounjaro addresses what the clinical evidence says about appetite and weight after treatment ends. And for a broader view of the full range of evidence-based weight management options, it helps to see the whole landscape before deciding on next steps.

People also sometimes notice significant hunger returning when a supply delay means they miss an injection. That is covered separately, but the short answer is: missing a dose matters clinically, and your prescriber should know about it rather than you restarting independently at a different dose.

What you can do, and what needs clinical input

Some things that reliably worsen returning hunger on Mounjaro are within your control. Skipping meals entirely (which some people do when appetite is low) can destabilise blood sugar in ways that increase hunger signals a few hours later. Eating too little protein at each meal removes a key satiety signal. Poor sleep substantially elevates ghrelin, the hormone that drives appetite. High stress raises cortisol, which directly stimulates hunger, and our page on why hunger changes during Mounjaro treatment goes into more detail on all of these mechanisms. None of those are character flaws; they are biology, and addressing them can meaningfully restore the appetite suppression that feels like it has slipped.

What needs clinical input: if hunger is returning consistently despite stable sleep, meals and stress levels; if you feel the current dose has genuinely plateaued after several weeks; or if you are considering stopping treatment because the returning hunger feels unmanageable, including if that hunger is accompanied by the kind of sharp, cramping discomfort covered in our guide to hunger pains on Mounjaro. These are conversations for a prescriber. The NHS guidance on tirzepatide is also a useful reference for what side-effect patterns and changes in experience to report to your clinical team. If you have questions about how your treatment is being managed or want to speak directly with the team, our support line is available seven days a week.

Mounjaro is a prescription-only medicine, and the right dose at the right stage of your treatment is a clinical decision. If you have not yet started treatment and are considering it, you can find out more about whether it might be suitable through a free consultation with our prescribers.